SDC3 Genotype

Your weight, your blood pressure response to medication, and even your long-term brain health are shaped by genes you inherited at birth. SDC3 (syndecan-3) is one of those genes, and specific variants in it have been linked in human studies to higher body weight, harder-to-treat high blood pressure, and altered immune signaling patterns seen in Alzheimer's disease.

This test reads the specific sequence of your SDC3 gene to see which variants you carry. It is a one-time test, because your genotype does not change. The result is most useful as a piece of context that helps explain why your body responds the way it does to weight gain, blood pressure treatment, or aging.

What SDC3 Actually Does

SDC3 codes for a protein that sits on the outside of cells and acts like a docking station for signals coming in from the outside. It is found mostly in the brain, where it helps regulate appetite and body weight by tuning the activity of brain circuits that tell you when to eat and when to stop. It is also present in muscle and other tissues, where it plays a role in cell movement, repair, and communication.

Because the protein affects appetite control, blood vessel function, and how immune cells behave, variants in the SDC3 gene can have downstream effects across several body systems. This is why a single gene shows up in research on obesity, blood pressure, and brain disease.

Obesity and Body Weight

This is the most consistent finding in the human evidence on SDC3. Specific variants in the gene have been tied to higher body weight in multiple ethnic groups, with effects that hold up across independent studies.

In a study of Korean women, two variants called rs2282440 (also known as T271I) and rs2491132 (V150I) were associated with obesity, defined as a BMI above 30. The link held in two separate groups of women, which is the kind of replication that makes a genetic finding more believable. A third variant tested in the same study, rs4949184, was not associated with obesity.

A Taiwanese study looked at seven different obesity-related gene variants and found that only rs2282440 in SDC3 was clearly tied to obesity in that population. Of note, this study used Taiwan's national threshold of BMI 27 or higher to define obesity, which is lower than the BMI 30 cutoff used in the Korean study. People with the T/T genotype were about twice as likely to be obese as people with other combinations. They also had larger waists and hips, higher body fat percentage, and lower HDL cholesterol, suggesting that the variant affects not just weight but the metabolic pattern that comes with it.

In European women being evaluated for infertility, a rare variant called T329I was linked to obesity, and a different variant called V208I was linked to several hormones involved in androgen balance, including luteinizing hormone, androstenedione, sex hormone-binding globulin, and 17-hydroxyprogesterone. This suggests SDC3 may sit at the intersection of weight regulation and reproductive hormones in women.

What this means for you: If you carry one of these obesity-associated variants, it does not guarantee you will become obese, but it suggests your biology may push harder in that direction. That information can change how aggressively you act on diet, sleep, and exercise habits, and how closely you monitor weight, waist size, and HDL cholesterol over time.

Treatment-Resistant High Blood Pressure

A genome-wide study of about 1,700 people identified SDC3 as a gene linked to apparent treatment-resistant hypertension, meaning blood pressure that stays high despite multiple medications. The risk-associated variants were tied to lower SDC3 activity in artery and skeletal muscle tissue. People with treatment-resistant high blood pressure also had lower SDC3 levels in their immune cells compared to people with regular high blood pressure or normal blood pressure.

This finding has not yet been independently confirmed. A larger 2025 genome-wide study using UK Biobank and FinnGen data did not replicate SDC3 as a significant locus for treatment-resistant hypertension, and instead pointed to other genes such as CASZ1, WNT2B, KCNK3, LSP1, and EVX1. So the SDC3 link should be treated as a preliminary signal until more data accumulates.

What this means for you: If you have hypertension that has been difficult to control on standard medications, knowing your SDC3 status may eventually become part of a workup for why standard treatment is not working. Today, this is research territory, not a routine clinical decision tool, but it is a marker worth knowing about if treatment resistance runs in your family.

Alzheimer's Disease and Brain Aging

In a study of 42 adults, the amount of SDC3 protein expressed in immune cells circulating in blood was higher in people with Alzheimer's disease than in people without it. SDC3 alone gave moderate ability to tell the two groups apart, but when researchers combined it with another blood marker called p-tau217 (a protein fragment that signals Alzheimer's brain changes) and the person's age, the combined score was stronger.

This work measured SDC3 protein expression, not the genotype directly, but the gene you inherit influences how much protein your cells make. So your SDC3 variant may be part of the upstream story behind the immune-related blood signal that researchers are now exploring in Alzheimer's. This is early science, and SDC3 genotype is not currently used to predict or diagnose Alzheimer's.

Other Conditions Under Investigation

Two other associations are reported in smaller, exploratory studies. A whole-exome reanalysis of 21 people with amyotrophic lateral sclerosis (ALS) found that several carried SDC3 variants that change the protein's electrical charge. These variants are currently classified as benign or likely benign, so the connection to ALS is a research hypothesis, not a clinical finding. In African American women, several SDC3 variants were linked to higher odds of high-grade precancerous cervical lesions, especially in women infected with certain high-risk types of human papillomavirus (HPV).

These findings are useful context but should not change clinical decisions on their own. They reflect early-stage human research where the SDC3 connection needs to be confirmed in larger, independent groups.

One-Time Result, Long-Term Use

This is a genetic test. Your SDC3 genotype is set at conception and will be the same if you test it again next year, in ten years, or ever. There is no need to retest unless there is a reason to question the accuracy of the original result (for example, a different lab method might be used to confirm an unexpected variant). The point of testing is not to track a number over time. It is to get the information once and use it to shape decisions over the rest of your life.

What does need ongoing tracking is the downstream phenotype. If you carry an obesity-associated variant, that is a reason to monitor body composition, waist circumference, HDL cholesterol, fasting insulin, and HOMA-IR (a calculation that estimates insulin resistance) on a regular cadence, ideally at least once a year. If you carry a variant linked to treatment-resistant hypertension, more frequent blood pressure monitoring and earlier escalation of management make sense.

Decision Pathway for an Unexpected Result

If your SDC3 genotype shows one of the variants associated with obesity, the next step is to look at the rest of your metabolic picture. A comprehensive metabolic panel, lipid panel, fasting insulin, HbA1c (a three-month average of blood sugar), and body composition measurement together tell you whether the genetic tendency is already being expressed in your biology. If those markers are clean, that is reassurance that lifestyle is keeping the risk in check. If any are drifting in the wrong direction, the genotype gives you a reason to act earlier than you might otherwise.

If you have treatment-resistant high blood pressure and carry a risk allele in SDC3, that is a reason to involve a hypertension specialist or cardiologist sooner rather than later, and to look at secondary causes of resistant hypertension more carefully. If you carry variants and have a family history of early Alzheimer's disease, consider adding longitudinal cognitive monitoring and emerging blood biomarkers (such as p-tau217) over time.

When a Genetic Result Can Be Misleading

Genetic tests have their own confounders that differ from blood-based markers. Keep these in mind before reading too much into a single result:

• Variant panel coverage: the test only detects the specific positions in the gene it is designed to look at. A negative result does not rule out rare or unusual variants elsewhere in SDC3.
• Ancestry matters: the obesity-linked variants studied in Korean and Taiwanese populations may have different frequencies and effect sizes in other ancestries. A finding that is meaningful in one population may not carry the same weight in another.
• Variants of uncertain significance: some variants reported in research, including most SDC3 variants studied in ALS, are currently classified as benign. Carrying one of these does not mean you have the associated condition.
• Research-grade vs clinical-grade testing: direct-to-consumer reports may use different methods than clinical-grade sequencing and can occasionally produce different calls at the same position.

Why This Is Still a Research Marker

SDC3 genotype testing does not yet have standardized clinical guidelines, agreed-upon risk thresholds, or formal recommendations from medical societies. The evidence base is small, mostly from observational studies of a few hundred to a few thousand people, and most associations have not been confirmed in large prospective cohorts. The treatment-resistant hypertension link, for example, was not replicated in a larger 2025 genome-wide study. That does not mean the result is useless. It means you should treat it as one piece of context alongside your standard labs, your family history, and your own measured phenotype, not as a verdict.